Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Zydus, Torrent Pharma join hands to co-market Semaglutide injection
Zydus Lifesciences and Torrent Pharmaceuticals have joined forces to bring a new diabetes and weight management medication to India. Zydus will manufacture the Semaglutide Injection, while Torrent Pharma will co-market it under its brand name Sembolic. This collaboration aims to leverage Torrent's strong presence in chronic therapies and its extensive field force across the country.
Zydus partners with Lupin to co-market generic semaglutide in India
Zydus Lifesciences and Lupin are joining forces. They will make a generic version of the popular weight-loss and diabetes drug semaglutide more accessible in India. This collaboration follows the upcoming expiry of Novo Nordisk's patent. Lupin will co-market Zydus's semaglutide injection under its own brand. This move aims to reach more patients across the country.
Zydus, Lupin sign pact to co-market weight-loss Semaglutide injection in India
Zydus Lifesciences and Lupin have joined forces to bring Semaglutide Injection to India. This medication helps manage type 2 diabetes and aids in chronic weight management. This collaboration aims to provide advanced therapies for metabolic disorders across the nation.
Zydus to launch CGM devices with AI-intelligence powered insights
Zydus Lifesciences announced its new offering companion diagnostics portfolio. The company will be launching Diasens and GlucoLive, next-generation Continuous Glucose Monitoring (CGM) devices that combine artificial intelligence powered insights, and integrated remote care capabilities. The CGM system is designed to monitor glucose with an integrated AI layer to provide analytics and enable a closed-loop care ecosystem connecting patients, caregivers, and clinicians in real time.
Zydus Life launches AI glucose monitors for real-time diabetes tracking
Zydus Lifesciences launched AI-powered CGM devices, Diasens and GlucoLive, for diabetes and CKD patients, offering continuous glucose monitoring and remote access via the GoodFlip app.
Zydus Lifesciences gets USFDA nod to market generic drugs
Zydus Lifesciences has won regulatory clearance in the United States to launch generic Ivermectin and Dapsone tablets. Used to treat parasitic worm infections and leprosy, the approval signals progress in the company's US growth strategy and broadens its market footprint.
Zydus receives USFDA approval for Ivermectin Tablets USP, 3 mg and Dapsone Tablets USP, 25 mg and 100 mg
Zydus Lifesciences has received final approvals from the United States Food and Drug Administration (USFDA) for Ivermectin Tablets USP, 3 mg (USRLD: Stromectol Tablets, 3 mg) and Dapsone Tablets USP, 25 mg and 100 mg (USRLD: Dapsone Tablets USP, 25 mg and 100 mg).
Zydus Lifesciences moves closer to US launch of key cancer drug biosimilar
Zydus Lifesciences’ in-licensed pembrolizumab biosimilar met the primary endpoint in a pivotal PK study, paving the way for a near-term USFDA filing and entry into the North American market.
Zydus Lifesciences in focus after USFDA clears Ahmedabad plant, Aflibercept biosimilar launch
Zydus Lifesciences is in focus after receiving USFDA clearance with zero observations for its Ahmedabad facility and launching ANYRA, India’s first indigenous Aflibercept biosimilar. The developments strengthen its regulatory standing and expand its ophthalmology portfolio, positioning the company to tap into a large and growing domestic market for retinal therapies.
Stocks to Watch for Feb 19: Zydus Life, TVS Motor, NCC, Jindal Saw and more
From NCC and its step-down subsidiary OB Infrastructure receiving an order of debarment from the NHAI to Zydus Lifesciences getting final approval from the USFDA for bosentan tablets for oral suspension, these are some of the stocks to watch out ahead of Thursday's trading session.
Zydus Life gets FDA nod for children’s lung treatment drug bosentan
Zydus Lifesciences Ltd received US FDA approval for bosentan tablets for oral suspension, 32 mg, for pulmonary arterial hypertension (PAH) treatment. Shares of Zydus Lifesciences Ltd ended marginally higher on Wednesday, February 18, by 0.65% at ₹912.50 on the NSE.
Momentum Stocks: Kalyan Jewellers, Sterlite Technologies, Usha Financial see negative breakdowns
Cemindia Projects, Titan Company, Gland Pharma, Granules India, Zydus Lifesciences, GMR Airports, JB Chemicals & Pharmaceuticals, Torrent Pharmaceuticals, among others hit 52-week high.